00002004061/12022Q1FALSE00002004062022-01-032022-04-030000200406us-gaap:CommonStockMember2022-01-032022-04-030000200406jnj:A0.650NotesDue2024Member2022-01-032022-04-030000200406jnj:A5.50NotesDue2024Member2022-01-032022-04-030000200406jnj:A1.150NotesDue2028Member2022-01-032022-04-030000200406jnj:A1.650NotesDue2035Member2022-01-032022-04-0300002004062022-04-22xbrli:shares00002004062022-04-03iso4217:USD00002004062022-01-02iso4217:USDxbrli:sharesxbrli:pure00002004062021-01-042021-04-040000200406us-gaap:RetainedEarningsMember2022-01-020000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-020000200406us-gaap:CommonStockMember2022-01-020000200406us-gaap:TreasuryStockMember2022-01-020000200406us-gaap:RetainedEarningsMember2022-01-032022-04-030000200406us-gaap:TreasuryStockMember2022-01-032022-04-030000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-032022-04-030000200406us-gaap:RetainedEarningsMember2022-04-030000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-030000200406us-gaap:CommonStockMember2022-04-030000200406us-gaap:TreasuryStockMember2022-04-0300002004062021-01-030000200406us-gaap:RetainedEarningsMember2021-01-030000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-030000200406us-gaap:CommonStockMember2021-01-030000200406us-gaap:TreasuryStockMember2021-01-030000200406us-gaap:RetainedEarningsMember2021-01-042021-04-040000200406us-gaap:TreasuryStockMember2021-01-042021-04-040000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-042021-04-0400002004062021-04-040000200406us-gaap:RetainedEarningsMember2021-04-040000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-040000200406us-gaap:CommonStockMember2021-04-040000200406us-gaap:TreasuryStockMember2021-04-040000200406jnj:PatentsAndTrademarksMember2022-04-030000200406jnj:PatentsAndTrademarksMember2022-01-020000200406us-gaap:OtherIntangibleAssetsMember2022-04-030000200406us-gaap:OtherIntangibleAssetsMember2022-01-020000200406us-gaap:TrademarksMember2022-04-030000200406us-gaap:TrademarksMember2022-01-020000200406jnj:PurchasedInProcessResearchAndDevelopmentMember2022-04-030000200406jnj:PurchasedInProcessResearchAndDevelopmentMember2022-01-020000200406us-gaap:InProcessResearchAndDevelopmentMemberjnj:BermekimabMember2022-01-032022-04-030000200406jnj:ConsumerMember2022-01-020000200406jnj:PharmaceuticalMember2022-01-020000200406jnj:MedicalDevicesMember2022-01-020000200406jnj:ConsumerMember2022-01-032022-04-030000200406jnj:PharmaceuticalMember2022-01-032022-04-030000200406jnj:MedicalDevicesMember2022-01-032022-04-030000200406jnj:ConsumerMember2022-04-030000200406jnj:PharmaceuticalMember2022-04-030000200406jnj:MedicalDevicesMember2022-04-030000200406jnj:PatentsAndTrademarksMember2022-01-032022-04-030000200406us-gaap:OtherIntangibleAssetsMember2022-01-032022-04-030000200406us-gaap:ForeignExchangeContractMember2022-04-030000200406us-gaap:CrossCurrencyInterestRateContractMember2022-04-030000200406us-gaap:InterestRateSwapMember2022-04-030000200406us-gaap:ForeignExchangeContractMember2022-01-020000200406us-gaap:CrossCurrencyInterestRateContractMember2022-01-020000200406us-gaap:InterestRateSwapMember2022-01-020000200406us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:SalesMember2022-01-032022-04-030000200406us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:CostOfSalesMember2022-01-032022-04-030000200406us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-032022-04-030000200406us-gaap:FairValueHedgingMemberjnj:InterestIncomeExpenseNetMemberus-gaap:InterestRateSwapMember2022-01-032022-04-030000200406us-gaap:FairValueHedgingMemberjnj:OtherIncomeExpenseNetMemberus-gaap:InterestRateSwapMember2022-01-032022-04-030000200406us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:SalesMember2021-01-042021-04-040000200406us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:CostOfSalesMember2021-01-042021-04-040000200406us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-042021-04-040000200406us-gaap:FairValueHedgingMemberjnj:InterestIncomeExpenseNetMemberus-gaap:InterestRateSwapMember2021-01-042021-04-040000200406us-gaap:FairValueHedgingMemberjnj:OtherIncomeExpenseNetMemberus-gaap:InterestRateSwapMember2021-01-042021-04-040000200406us-gaap:NetInvestmentHedgingMemberus-gaap:NetInvestmentHedgingMemberus-gaap:SalesMember2022-01-032022-04-030000200406us-gaap:NetInvestmentHedgingMemberus-gaap:CostOfSalesMemberus-gaap:NetInvestmentHedgingMember2022-01-032022-04-030000200406us-gaap:NetInvestmentHedgingMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:NetInvestmentHedgingMember2022-01-032022-04-030000200406jnj:InterestIncomeExpenseNetMemberus-gaap:NetInvestmentHedgingMemberus-gaap:NetInvestmentHedgingMember2022-01-032022-04-030000200406jnj:OtherIncomeExpenseNetMemberus-gaap:NetInvestmentHedgingMemberus-gaap:NetInvestmentHedgingMember2022-01-032022-04-030000200406us-gaap:NetInvestmentHedgingMemberus-gaap:NetInvestmentHedgingMemberus-gaap:SalesMember2021-01-042021-04-040000200406us-gaap:NetInvestmentHedgingMemberus-gaap:CostOfSalesMemberus-gaap:NetInvestmentHedgingMember2021-01-042021-04-040000200406us-gaap:NetInvestmentHedgingMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:NetInvestmentHedgingMember2021-01-042021-04-040000200406jnj:InterestIncomeExpenseNetMemberus-gaap:NetInvestmentHedgingMemberus-gaap:NetInvestmentHedgingMember2021-01-042021-04-040000200406jnj:OtherIncomeExpenseNetMemberus-gaap:NetInvestmentHedgingMemberus-gaap:NetInvestmentHedgingMember2021-01-042021-04-040000200406us-gaap:CashFlowHedgingMemberus-gaap:SalesMemberus-gaap:ForeignExchangeContractMember2022-01-032022-04-030000200406us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-01-032022-04-030000200406us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-01-032022-04-030000200406jnj:InterestIncomeExpenseNetMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-01-032022-04-030000200406jnj:OtherIncomeExpenseNetMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-01-032022-04-030000200406us-gaap:CashFlowHedgingMemberus-gaap:SalesMemberus-gaap:ForeignExchangeContractMember2021-01-042021-04-040000200406us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-042021-04-040000200406us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-042021-04-040000200406jnj:InterestIncomeExpenseNetMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-042021-04-040000200406jnj:OtherIncomeExpenseNetMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-042021-04-040000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:SalesMember2022-01-032022-04-030000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMember2022-01-032022-04-030000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CashFlowHedgingMember2022-01-032022-04-030000200406us-gaap:CrossCurrencyInterestRateContractMemberjnj:InterestIncomeExpenseNetMemberus-gaap:CashFlowHedgingMember2022-01-032022-04-030000200406us-gaap:CrossCurrencyInterestRateContractMemberjnj:OtherIncomeExpenseNetMemberus-gaap:CashFlowHedgingMember2022-01-032022-04-030000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:SalesMember2021-01-042021-04-040000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMember2021-01-042021-04-040000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CashFlowHedgingMember2021-01-042021-04-040000200406us-gaap:CrossCurrencyInterestRateContractMemberjnj:InterestIncomeExpenseNetMemberus-gaap:CashFlowHedgingMember2021-01-042021-04-040000200406us-gaap:CrossCurrencyInterestRateContractMemberjnj:OtherIncomeExpenseNetMemberus-gaap:CashFlowHedgingMember2021-01-042021-04-040000200406us-gaap:LongTermDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-04-030000200406us-gaap:LongTermDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-020000200406jnj:OtherIncomeExpenseNetMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-01-032022-04-030000200406jnj:OtherIncomeExpenseNetMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-01-042021-04-040000200406jnj:OtherIncomeExpenseNetMember2022-01-032022-04-030000200406jnj:OtherIncomeExpenseNetMember2021-01-042021-04-040000200406us-gaap:CrossCurrencyInterestRateContractMember2022-01-032022-04-030000200406us-gaap:CrossCurrencyInterestRateContractMember2021-01-042021-04-040000200406us-gaap:CrossCurrencyInterestRateContractMemberjnj:OtherIncomeExpenseNetMember2022-01-032022-04-030000200406us-gaap:CrossCurrencyInterestRateContractMemberjnj:OtherIncomeExpenseNetMember2021-01-042021-04-040000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithReadilyDeterminableValueMember2022-01-020000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithReadilyDeterminableValueMember2022-01-032022-04-030000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithReadilyDeterminableValueMember2022-04-030000200406jnj:EquityInvestmentswithoutReadilyDeterminableValueMemberus-gaap:EquitySecuritiesMember2022-01-020000200406jnj:EquityInvestmentswithoutReadilyDeterminableValueMemberus-gaap:EquitySecuritiesMember2022-01-032022-04-030000200406jnj:EquityInvestmentswithoutReadilyDeterminableValueMemberus-gaap:EquitySecuritiesMember2022-04-030000200406us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2022-04-030000200406us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2022-04-030000200406us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2022-04-030000200406us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2022-01-020000200406us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel1Member2022-04-030000200406us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel2Member2022-04-030000200406us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel3Member2022-04-030000200406us-gaap:InterestRateContractMember2022-04-030000200406us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel2Member2022-01-020000200406us-gaap:FairValueInputsLevel1Member2022-04-030000200406us-gaap:FairValueInputsLevel2Member2022-04-030000200406us-gaap:FairValueInputsLevel3Member2022-04-030000200406us-gaap:FairValueInputsLevel2Member2022-01-020000200406us-gaap:FairValueInputsLevel1Member2022-01-020000200406us-gaap:FairValueInputsLevel3Member2022-01-020000200406jnj:AurisHealthMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-04-030000200406jnj:AurisHealthMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-01-020000200406us-gaap:OtherCurrentLiabilitiesMember2022-04-030000200406us-gaap:OtherCurrentLiabilitiesMember2022-01-020000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:CashMember2022-04-030000200406us-gaap:SovereignDebtSecuritiesMemberus-gaap:HeldtomaturitySecuritiesMember2022-04-030000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember2022-04-030000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2022-04-030000200406us-gaap:MoneyMarketFundsMemberus-gaap:HeldtomaturitySecuritiesMember2022-04-030000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:BankTimeDepositsMember2022-04-030000200406us-gaap:HeldtomaturitySecuritiesMember2022-04-030000200406us-gaap:USTreasuryAndGovernmentMemberus-gaap:AvailableforsaleSecuritiesMember2022-04-030000200406us-gaap:SovereignDebtSecuritiesMemberus-gaap:AvailableforsaleSecuritiesMember2022-04-030000200406us-gaap:CorporateDebtSecuritiesMemberus-gaap:AvailableforsaleSecuritiesMember2022-04-030000200406us-gaap:AvailableforsaleSecuritiesMember2022-04-030000200406us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A6.73Debenturesdue2023Member2022-04-030000200406us-gaap:CarryingReportedAmountFairValueDisclosureMemberjnj:A6.73Debenturesdue2023Member2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A6.73Debenturesdue2023Member2022-04-030000200406jnj:A3.375Notesdue2023Member2022-04-030000200406jnj:A3.375Notesdue2023Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A3.375Notesdue2023Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A0.650NotesDue2024Member2022-04-030000200406jnj:A0.650NotesDue2024Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A0.650NotesDue2024Member2022-04-030000200406jnj:A5.50NotesDue2024Member2022-04-030000200406jnj:A5.50NotesDue2024Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A5.50NotesDue2024Member2022-04-030000200406jnj:A2.625Notesdue2025Member2022-04-030000200406jnj:A2.625Notesdue2025Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A2.625Notesdue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A0550NotesDue2025Member2022-04-030000200406jnj:A0550NotesDue2025Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A0550NotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A2.45Notesdue2026Member2022-04-030000200406jnj:A2.45Notesdue2026Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A2.45Notesdue2026Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A2.95Notesdue2027Member2022-04-030000200406jnj:A2.95Notesdue2027Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A2.95Notesdue2027Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A095NotesDue2027Member2022-04-030000200406jnj:A095NotesDue2027Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A095NotesDue2027Member2022-04-030000200406jnj:A2.900Notesdue2028Member2022-04-030000200406jnj:A2.900Notesdue2028Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A2.900Notesdue2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A1.150NotesDue2028Member2022-04-030000200406jnj:A1.150NotesDue2028Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A1.150NotesDue2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A6.95Notesdue2029Member2022-04-030000200406jnj:A6.95Notesdue2029Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A6.95Notesdue2029Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A1300NotesDue2030Member2022-04-030000200406jnj:A1300NotesDue2030Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A1300NotesDue2030Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A4.95Debenturesdue2033Member2022-04-030000200406jnj:A4.95Debenturesdue2033Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A4.95Debenturesdue2033Member2022-04-030000200406jnj:A4.375Notesdue2033Member2022-04-030000200406jnj:A4.375Notesdue2033Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A4.375Notesdue2033Member2022-04-030000200406jnj:A1.650NotesDue2035Member2022-04-030000200406jnj:A1.650NotesDue2035Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A1.650NotesDue2035Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A3.55Notesdue2036Member2022-04-030000200406jnj:A3.55Notesdue2036Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A3.55Notesdue2036Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A5.95Notesdue2037Member2022-04-030000200406jnj:A5.95Notesdue2037Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A5.95Notesdue2037Member2022-04-030000200406jnj:A3.625Notesdue2037Member2022-04-030000200406jnj:A3.625Notesdue2037Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A3.625Notesdue2037Member2022-04-030000200406jnj:A3.400Notesdue2038Member2022-04-030000200406jnj:A3.400Notesdue2038Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A3.400Notesdue2038Member2022-04-030000200406jnj:A5.85Debenturesdue2038Member2022-04-030000200406jnj:A5.85Debenturesdue2038Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A5.85Debenturesdue2038Member2022-04-030000200406jnj:A4.50Debenturesdue2040Member2022-04-030000200406jnj:A4.50Debenturesdue2040Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A4.50Debenturesdue2040Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A210NotesDue2040Member2022-04-030000200406jnj:A210NotesDue2040Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A210NotesDue2040Member2022-04-030000200406jnj:A4.85Notesdue2041Member2022-04-030000200406jnj:A4.85Notesdue2041Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406us-gaap:EstimateOfFairValueFairValueDisclosureMemberjnj:A4.85Notesdue2041Member2022-04-030000200406jnj:A4.50Notesdue2043Member2022-04-030000200406jnj:A4.50Notesdue2043Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A4.50Notesdue2043Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A3.70Notesdue2046Member2022-04-030000200406jnj:A3.70Notesdue2046Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A3.70Notesdue2046Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A3.75Notesdue2047Member2022-04-030000200406jnj:A3.75Notesdue2047Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A3.75Notesdue2047Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A3.500Notesdue2048Member2022-04-030000200406jnj:A3.500Notesdue2048Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A3.500Notesdue2048Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A2250NotesDue2050Member2022-04-030000200406jnj:A2250NotesDue2050Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A2250NotesDue2050Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:A2450NotesDue2060Member2022-04-030000200406jnj:A2450NotesDue2060Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:A2450NotesDue2060Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-030000200406jnj:NotesDuePeriodFifteenMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-030000200406jnj:NotesDuePeriodFifteenMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-0300002004062021-01-042022-01-020000200406us-gaap:CommercialPaperMember2022-04-030000200406us-gaap:CommercialPaperMember2022-01-032022-04-030000200406us-gaap:PensionPlansDefinedBenefitMember2022-01-032022-04-030000200406us-gaap:PensionPlansDefinedBenefitMember2021-01-042021-04-040000200406us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-032022-04-030000200406us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-042021-04-040000200406country:US2022-01-032022-04-030000200406us-gaap:ForeignPlanMember2022-01-032022-04-030000200406us-gaap:AccumulatedTranslationAdjustmentMember2022-01-020000200406us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-020000200406us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-020000200406us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-020000200406us-gaap:AccumulatedTranslationAdjustmentMember2022-01-032022-04-030000200406us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-032022-04-030000200406us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-032022-04-030000200406us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-032022-04-030000200406us-gaap:AccumulatedTranslationAdjustmentMember2022-04-030000200406us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-04-030000200406us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-04-030000200406us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-04-030000200406jnj:OTCMembercountry:USjnj:ConsumerMember2022-01-032022-04-030000200406jnj:OTCMembercountry:USjnj:ConsumerMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:OTCMemberjnj:ConsumerMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:OTCMemberjnj:ConsumerMember2021-01-042021-04-040000200406jnj:OTCMemberjnj:ConsumerMember2022-01-032022-04-030000200406jnj:OTCMemberjnj:ConsumerMember2021-01-042021-04-040000200406jnj:BeautyMembercountry:USjnj:ConsumerMember2022-01-032022-04-030000200406jnj:BeautyMembercountry:USjnj:ConsumerMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:BeautyMemberjnj:ConsumerMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:BeautyMemberjnj:ConsumerMember2021-01-042021-04-040000200406jnj:BeautyMemberjnj:ConsumerMember2022-01-032022-04-030000200406jnj:BeautyMemberjnj:ConsumerMember2021-01-042021-04-040000200406country:USjnj:OralCareMemberjnj:ConsumerMember2022-01-032022-04-030000200406country:USjnj:OralCareMemberjnj:ConsumerMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:OralCareMemberjnj:ConsumerMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:OralCareMemberjnj:ConsumerMember2021-01-042021-04-040000200406jnj:OralCareMemberjnj:ConsumerMember2022-01-032022-04-030000200406jnj:OralCareMemberjnj:ConsumerMember2021-01-042021-04-040000200406country:USjnj:BabyCareMemberjnj:ConsumerMember2022-01-032022-04-030000200406country:USjnj:BabyCareMemberjnj:ConsumerMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:BabyCareMemberjnj:ConsumerMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:BabyCareMemberjnj:ConsumerMember2021-01-042021-04-040000200406jnj:BabyCareMemberjnj:ConsumerMember2022-01-032022-04-030000200406jnj:BabyCareMemberjnj:ConsumerMember2021-01-042021-04-040000200406jnj:WomensHealthMembercountry:USjnj:ConsumerMember2022-01-032022-04-030000200406jnj:WomensHealthMembercountry:USjnj:ConsumerMember2021-01-042021-04-040000200406jnj:WomensHealthMemberus-gaap:NonUsMemberjnj:ConsumerMember2022-01-032022-04-030000200406jnj:WomensHealthMemberus-gaap:NonUsMemberjnj:ConsumerMember2021-01-042021-04-040000200406jnj:WomensHealthMemberjnj:ConsumerMember2022-01-032022-04-030000200406jnj:WomensHealthMemberjnj:ConsumerMember2021-01-042021-04-040000200406country:USjnj:WoundCareandOtherMemberjnj:ConsumerMember2022-01-032022-04-030000200406country:USjnj:WoundCareandOtherMemberjnj:ConsumerMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:WoundCareandOtherMemberjnj:ConsumerMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:WoundCareandOtherMemberjnj:ConsumerMember2021-01-042021-04-040000200406jnj:WoundCareandOtherMemberjnj:ConsumerMember2022-01-032022-04-030000200406jnj:WoundCareandOtherMemberjnj:ConsumerMember2021-01-042021-04-040000200406country:USjnj:ConsumerMember2022-01-032022-04-030000200406country:USjnj:ConsumerMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:ConsumerMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:ConsumerMember2021-01-042021-04-040000200406jnj:ConsumerMember2021-01-042021-04-040000200406jnj:ImmunologyMemberjnj:PharmaceuticalMembercountry:US2022-01-032022-04-030000200406jnj:ImmunologyMemberjnj:PharmaceuticalMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:ImmunologyMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406jnj:ImmunologyMemberjnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:RemicadeMemberjnj:ImmunologyMemberjnj:PharmaceuticalMembercountry:US2022-01-032022-04-030000200406jnj:RemicadeMemberjnj:ImmunologyMemberjnj:PharmaceuticalMembercountry:US2021-01-042021-04-040000200406jnj:RemicadeMemberjnj:ImmunologyMemberjnj:UNITEDSTATESExportsMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406jnj:RemicadeMemberjnj:ImmunologyMemberjnj:UNITEDSTATESExportsMemberjnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:RemicadeMemberus-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406jnj:RemicadeMemberus-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:RemicadeMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406jnj:RemicadeMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:SimponiSimponiAriaMembercountry:US2022-01-032022-04-030000200406jnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:SimponiSimponiAriaMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:SimponiSimponiAriaMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:SimponiSimponiAriaMember2021-01-042021-04-040000200406jnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:SimponiSimponiAriaMember2022-01-032022-04-030000200406jnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:SimponiSimponiAriaMember2021-01-042021-04-040000200406jnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:StelaraMembercountry:US2022-01-032022-04-030000200406jnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:StelaraMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:StelaraMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:StelaraMember2021-01-042021-04-040000200406jnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:StelaraMember2022-01-032022-04-030000200406jnj:ImmunologyMemberjnj:PharmaceuticalMemberjnj:StelaraMember2021-01-042021-04-040000200406jnj:TremfyaMemberjnj:ImmunologyMemberjnj:PharmaceuticalMembercountry:US2022-01-032022-04-030000200406jnj:TremfyaMemberjnj:ImmunologyMemberjnj:PharmaceuticalMembercountry:US2021-01-042021-04-040000200406jnj:TremfyaMemberus-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406jnj:TremfyaMemberus-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:TremfyaMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406jnj:TremfyaMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:OtherImmunologyMemberjnj:ImmunologyMemberjnj:PharmaceuticalMembercountry:US2022-01-032022-04-030000200406jnj:OtherImmunologyMemberjnj:ImmunologyMemberjnj:PharmaceuticalMembercountry:US2021-01-042021-04-040000200406jnj:OtherImmunologyMemberus-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406jnj:OtherImmunologyMemberus-gaap:NonUsMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:OtherImmunologyMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406jnj:OtherImmunologyMemberjnj:ImmunologyMemberjnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:InfectiousDiseasesMembercountry:US2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:InfectiousDiseasesMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:InfectiousDiseasesMembercountry:USjnj:COVID19Member2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:InfectiousDiseasesMembercountry:USjnj:COVID19Member2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMemberjnj:COVID19Member2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMemberjnj:COVID19Member2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:InfectiousDiseasesMemberjnj:COVID19Member2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:InfectiousDiseasesMemberjnj:COVID19Member2021-01-042021-04-040000200406jnj:EDURANTrilpivirineMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMembercountry:US2022-01-032022-04-030000200406jnj:EDURANTrilpivirineMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:EDURANTrilpivirineMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:EDURANTrilpivirineMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2021-01-042021-04-040000200406jnj:EDURANTrilpivirineMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2022-01-032022-04-030000200406jnj:EDURANTrilpivirineMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2021-01-042021-04-040000200406jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMembercountry:US2022-01-032022-04-030000200406jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2021-01-042021-04-040000200406jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2022-01-032022-04-030000200406jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2021-01-042021-04-040000200406jnj:OtherInfectiousDiseasesMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMembercountry:US2022-01-032022-04-030000200406jnj:OtherInfectiousDiseasesMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMembercountry:US2021-01-042021-04-040000200406jnj:OtherInfectiousDiseasesMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2022-01-032022-04-030000200406jnj:OtherInfectiousDiseasesMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2021-01-042021-04-040000200406jnj:OtherInfectiousDiseasesMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2022-01-032022-04-030000200406jnj:OtherInfectiousDiseasesMemberjnj:PharmaceuticalMemberjnj:InfectiousDiseasesMember2021-01-042021-04-040000200406jnj:PharmaceuticalMembercountry:USjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:PharmaceuticalMembercountry:USjnj:NeuroscienceMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:CONCERTAMethylphenidateMemberjnj:PharmaceuticalMembercountry:USjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:CONCERTAMethylphenidateMemberjnj:PharmaceuticalMembercountry:USjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:CONCERTAMethylphenidateMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:CONCERTAMethylphenidateMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:CONCERTAMethylphenidateMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:CONCERTAMethylphenidateMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:PharmaceuticalMembercountry:USjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:PharmaceuticalMembercountry:USjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:RISPERDALCONSTAMembercountry:USjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:RISPERDALCONSTAMembercountry:USjnj:NeuroscienceMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:RISPERDALCONSTAMemberjnj:NeuroscienceMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:RISPERDALCONSTAMemberjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:RISPERDALCONSTAMemberjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:RISPERDALCONSTAMemberjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:OTHERNEUROSCIENCEMemberjnj:PharmaceuticalMembercountry:USjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:OTHERNEUROSCIENCEMemberjnj:PharmaceuticalMembercountry:USjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:OTHERNEUROSCIENCEMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:OTHERNEUROSCIENCEMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:OTHERNEUROSCIENCEMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2022-01-032022-04-030000200406jnj:OTHERNEUROSCIENCEMemberjnj:PharmaceuticalMemberjnj:NeuroscienceMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:OncologyMembercountry:US2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:OncologyMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:DARZALEXMemberjnj:PharmaceuticalMemberjnj:OncologyMembercountry:US2022-01-032022-04-030000200406jnj:DARZALEXMemberjnj:PharmaceuticalMemberjnj:OncologyMembercountry:US2021-01-042021-04-040000200406jnj:DARZALEXMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032022-04-030000200406jnj:DARZALEXMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:DARZALEXMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032022-04-030000200406jnj:DARZALEXMemberjnj:PharmaceuticalMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:ERLEADAMemberjnj:OncologyMembercountry:US2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:ERLEADAMemberjnj:OncologyMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:ERLEADAMemberjnj:OncologyMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:ERLEADAMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:ERLEADAMemberjnj:OncologyMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:ERLEADAMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:IMBRUVICAMemberjnj:PharmaceuticalMemberjnj:OncologyMembercountry:US2022-01-032022-04-030000200406jnj:IMBRUVICAMemberjnj:PharmaceuticalMemberjnj:OncologyMembercountry:US2021-01-042021-04-040000200406jnj:IMBRUVICAMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032022-04-030000200406jnj:IMBRUVICAMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:IMBRUVICAMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032022-04-030000200406jnj:IMBRUVICAMemberjnj:PharmaceuticalMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:ZYTIGAMemberjnj:PharmaceuticalMemberjnj:OncologyMembercountry:US2022-01-032022-04-030000200406jnj:ZYTIGAMemberjnj:PharmaceuticalMemberjnj:OncologyMembercountry:US2021-01-042021-04-040000200406jnj:ZYTIGAMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032022-04-030000200406jnj:ZYTIGAMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:ZYTIGAMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032022-04-030000200406jnj:ZYTIGAMemberjnj:PharmaceuticalMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:OtherOncologyMemberjnj:PharmaceuticalMemberjnj:OncologyMembercountry:US2022-01-032022-04-030000200406jnj:OtherOncologyMemberjnj:PharmaceuticalMemberjnj:OncologyMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:OtherOncologyMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:OtherOncologyMemberjnj:PharmaceuticalMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:OtherOncologyMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032022-04-030000200406jnj:OtherOncologyMemberjnj:PharmaceuticalMemberjnj:OncologyMember2021-01-042021-04-040000200406jnj:PharmaceuticalMembercountry:USjnj:PulmonaryHypertensionMember2022-01-032022-04-030000200406jnj:PharmaceuticalMembercountry:USjnj:PulmonaryHypertensionMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:OPSUMITMembercountry:USjnj:PulmonaryHypertensionMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:OPSUMITMembercountry:USjnj:PulmonaryHypertensionMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:OPSUMITMemberjnj:PulmonaryHypertensionMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:OPSUMITMemberjnj:PulmonaryHypertensionMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:OPSUMITMemberjnj:PulmonaryHypertensionMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:OPSUMITMemberjnj:PulmonaryHypertensionMember2021-01-042021-04-040000200406jnj:UPTRAVIMemberjnj:PharmaceuticalMembercountry:USjnj:PulmonaryHypertensionMember2022-01-032022-04-030000200406jnj:UPTRAVIMemberjnj:PharmaceuticalMembercountry:USjnj:PulmonaryHypertensionMember2021-01-042021-04-040000200406jnj:UPTRAVIMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMember2022-01-032022-04-030000200406jnj:UPTRAVIMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMember2021-01-042021-04-040000200406jnj:UPTRAVIMemberjnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMember2022-01-032022-04-030000200406jnj:UPTRAVIMemberjnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMember2021-01-042021-04-040000200406jnj:PharmaceuticalMembercountry:USjnj:PulmonaryHypertensionMemberjnj:OtherMember2022-01-032022-04-030000200406jnj:PharmaceuticalMembercountry:USjnj:PulmonaryHypertensionMemberjnj:OtherMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMemberjnj:OtherMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMemberjnj:OtherMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMemberjnj:OtherMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:PulmonaryHypertensionMemberjnj:OtherMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMembercountry:US2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMember2021-01-042021-04-040000200406jnj:XareltoMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMembercountry:US2022-01-032022-04-030000200406jnj:XareltoMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMembercountry:US2021-01-042021-04-040000200406jnj:XareltoMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMember2022-01-032022-04-030000200406jnj:XareltoMemberus-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMember2021-01-042021-04-040000200406jnj:XareltoMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMember2022-01-032022-04-030000200406jnj:XareltoMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMembercountry:USjnj:INVOKANAINVOKAMETMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMembercountry:USjnj:INVOKANAINVOKAMETMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMemberjnj:INVOKANAINVOKAMETMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMemberjnj:INVOKANAINVOKAMETMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMemberjnj:INVOKANAINVOKAMETMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMemberjnj:INVOKANAINVOKAMETMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMembercountry:USjnj:OtherMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMembercountry:USjnj:OtherMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMemberjnj:OtherMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMemberjnj:OtherMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMemberjnj:OtherMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberjnj:CardiovascularMetabolismOtherMemberjnj:OtherMember2021-01-042021-04-040000200406jnj:PharmaceuticalMembercountry:US2022-01-032022-04-030000200406jnj:PharmaceuticalMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:PharmaceuticalMember2021-01-042021-04-040000200406jnj:MedicalDevicesMembercountry:USjnj:InterventionalSolutionsMember2022-01-032022-04-030000200406jnj:MedicalDevicesMembercountry:USjnj:InterventionalSolutionsMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:InterventionalSolutionsMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:InterventionalSolutionsMember2021-01-042021-04-040000200406jnj:MedicalDevicesMemberjnj:InterventionalSolutionsMember2022-01-032022-04-030000200406jnj:MedicalDevicesMemberjnj:InterventionalSolutionsMember2021-01-042021-04-040000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMembercountry:US2022-01-032022-04-030000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMembercountry:US2021-01-042021-04-040000200406jnj:OrthopaedicsMemberus-gaap:NonUsMemberjnj:MedicalDevicesMember2022-01-032022-04-030000200406jnj:OrthopaedicsMemberus-gaap:NonUsMemberjnj:MedicalDevicesMember2021-01-042021-04-040000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMember2022-01-032022-04-030000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMember2021-01-042021-04-040000200406jnj:OrthopaedicsMemberjnj:HIPSMemberjnj:MedicalDevicesMembercountry:US2022-01-032022-04-030000200406jnj:OrthopaedicsMemberjnj:HIPSMemberjnj:MedicalDevicesMembercountry:US2021-01-042021-04-040000200406jnj:OrthopaedicsMemberus-gaap:NonUsMemberjnj:HIPSMemberjnj:MedicalDevicesMember2022-01-032022-04-030000200406jnj:OrthopaedicsMemberus-gaap:NonUsMemberjnj:HIPSMemberjnj:MedicalDevicesMember2021-01-042021-04-040000200406jnj:OrthopaedicsMemberjnj:HIPSMemberjnj:MedicalDevicesMember2022-01-032022-04-030000200406jnj:OrthopaedicsMemberjnj:HIPSMemberjnj:MedicalDevicesMember2021-01-042021-04-040000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMembercountry:USjnj:KNEESMember2022-01-032022-04-030000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMembercountry:USjnj:KNEESMember2021-01-042021-04-040000200406jnj:OrthopaedicsMemberus-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:KNEESMember2022-01-032022-04-030000200406jnj:OrthopaedicsMemberus-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:KNEESMember2021-01-042021-04-040000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMemberjnj:KNEESMember2022-01-032022-04-030000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMemberjnj:KNEESMember2021-01-042021-04-040000200406jnj:TRAUMAMemberjnj:OrthopaedicsMemberjnj:MedicalDevicesMembercountry:US2022-01-032022-04-030000200406jnj:TRAUMAMemberjnj:OrthopaedicsMemberjnj:MedicalDevicesMembercountry:US2021-01-042021-04-040000200406jnj:TRAUMAMemberjnj:OrthopaedicsMemberus-gaap:NonUsMemberjnj:MedicalDevicesMember2022-01-032022-04-030000200406jnj:TRAUMAMemberjnj:OrthopaedicsMemberus-gaap:NonUsMemberjnj:MedicalDevicesMember2021-01-042021-04-040000200406jnj:TRAUMAMemberjnj:OrthopaedicsMemberjnj:MedicalDevicesMember2022-01-032022-04-030000200406jnj:TRAUMAMemberjnj:OrthopaedicsMemberjnj:MedicalDevicesMember2021-01-042021-04-040000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMembercountry:USjnj:SPINEOTHERMember2022-01-032022-04-030000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMembercountry:USjnj:SPINEOTHERMember2021-01-042021-04-040000200406jnj:OrthopaedicsMemberus-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:SPINEOTHERMember2022-01-032022-04-030000200406jnj:OrthopaedicsMemberus-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:SPINEOTHERMember2021-01-042021-04-040000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMemberjnj:SPINEOTHERMember2022-01-032022-04-030000200406jnj:OrthopaedicsMemberjnj:MedicalDevicesMemberjnj:SPINEOTHERMember2021-01-042021-04-040000200406jnj:MedicalDevicesMemberjnj:SurgeryMembercountry:US2022-01-032022-04-030000200406jnj:MedicalDevicesMemberjnj:SurgeryMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:SurgeryMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:SurgeryMember2021-01-042021-04-040000200406jnj:MedicalDevicesMemberjnj:SurgeryMember2022-01-032022-04-030000200406jnj:MedicalDevicesMemberjnj:SurgeryMember2021-01-042021-04-040000200406jnj:ADVANCEDMemberjnj:MedicalDevicesMemberjnj:SurgeryMembercountry:US2022-01-032022-04-030000200406jnj:ADVANCEDMemberjnj:MedicalDevicesMemberjnj:SurgeryMembercountry:US2021-01-042021-04-040000200406jnj:ADVANCEDMemberus-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:SurgeryMember2022-01-032022-04-030000200406jnj:ADVANCEDMemberus-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:SurgeryMember2021-01-042021-04-040000200406jnj:ADVANCEDMemberjnj:MedicalDevicesMemberjnj:SurgeryMember2022-01-032022-04-030000200406jnj:ADVANCEDMemberjnj:MedicalDevicesMemberjnj:SurgeryMember2021-01-042021-04-040000200406jnj:GENERALMemberjnj:MedicalDevicesMemberjnj:SurgeryMembercountry:US2022-01-032022-04-030000200406jnj:GENERALMemberjnj:MedicalDevicesMemberjnj:SurgeryMembercountry:US2021-01-042021-04-040000200406jnj:GENERALMemberus-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:SurgeryMember2022-01-032022-04-030000200406jnj:GENERALMemberus-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:SurgeryMember2021-01-042021-04-040000200406jnj:GENERALMemberjnj:MedicalDevicesMemberjnj:SurgeryMember2022-01-032022-04-030000200406jnj:GENERALMemberjnj:MedicalDevicesMemberjnj:SurgeryMember2021-01-042021-04-040000200406jnj:MedicalDevicesMemberjnj:VisionMembercountry:US2022-01-032022-04-030000200406jnj:MedicalDevicesMemberjnj:VisionMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:VisionMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:VisionMember2021-01-042021-04-040000200406jnj:MedicalDevicesMemberjnj:VisionMember2022-01-032022-04-030000200406jnj:MedicalDevicesMemberjnj:VisionMember2021-01-042021-04-040000200406jnj:MedicalDevicesMemberjnj:VisionMembercountry:USjnj:CONTACTLENSESOTHERMember2022-01-032022-04-030000200406jnj:MedicalDevicesMemberjnj:VisionMembercountry:USjnj:CONTACTLENSESOTHERMember2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:VisionMemberjnj:CONTACTLENSESOTHERMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:VisionMemberjnj:CONTACTLENSESOTHERMember2021-01-042021-04-040000200406jnj:MedicalDevicesMemberjnj:VisionMemberjnj:CONTACTLENSESOTHERMember2022-01-032022-04-030000200406jnj:MedicalDevicesMemberjnj:VisionMemberjnj:CONTACTLENSESOTHERMember2021-01-042021-04-040000200406jnj:MedicalDevicesMemberjnj:SURGICALMemberjnj:VisionMembercountry:US2022-01-032022-04-030000200406jnj:MedicalDevicesMemberjnj:SURGICALMemberjnj:VisionMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:SURGICALMemberjnj:VisionMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:MedicalDevicesMemberjnj:SURGICALMemberjnj:VisionMember2021-01-042021-04-040000200406jnj:MedicalDevicesMemberjnj:SURGICALMemberjnj:VisionMember2022-01-032022-04-030000200406jnj:MedicalDevicesMemberjnj:SURGICALMemberjnj:VisionMember2021-01-042021-04-040000200406jnj:MedicalDevicesMembercountry:US2022-01-032022-04-030000200406jnj:MedicalDevicesMembercountry:US2021-01-042021-04-040000200406us-gaap:NonUsMemberjnj:MedicalDevicesMember2022-01-032022-04-030000200406us-gaap:NonUsMemberjnj:MedicalDevicesMember2021-01-042021-04-040000200406jnj:MedicalDevicesMember2021-01-042021-04-040000200406country:US2022-01-032022-04-030000200406country:US2021-01-042021-04-040000200406us-gaap:NonUsMember2022-01-032022-04-030000200406us-gaap:NonUsMember2021-01-042021-04-040000200406jnj:CONSUMERHEALTHAndPHARMACEUTICALMemberjnj:OTCMembercountry:CN2021-01-042021-04-040000200406us-gaap:OperatingSegmentsMemberjnj:ConsumerMember2022-01-032022-04-030000200406us-gaap:OperatingSegmentsMemberjnj:ConsumerMember2021-01-042021-04-040000200406jnj:PharmaceuticalMemberus-gaap:OperatingSegmentsMember2022-01-032022-04-030000200406jnj:PharmaceuticalMemberus-gaap:OperatingSegmentsMember2021-01-042021-04-040000200406jnj:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-01-032022-04-030000200406jnj:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-01-042021-04-040000200406us-gaap:OperatingSegmentsMember2022-01-032022-04-030000200406us-gaap:OperatingSegmentsMember2021-01-042021-04-040000200406us-gaap:CorporateNonSegmentMember2022-01-032022-04-030000200406us-gaap:CorporateNonSegmentMember2021-01-042021-04-040000200406jnj:BermekimabMemberjnj:PharmaceuticalMember2022-01-032022-04-030000200406srt:EuropeMember2022-01-032022-04-030000200406srt:EuropeMember2021-01-042021-04-040000200406jnj:WesternHemisphereExcludingUSMember2022-01-032022-04-030000200406jnj:WesternHemisphereExcludingUSMember2021-01-042021-04-040000200406jnj:AsiaPacificAfricaMember2022-01-032022-04-030000200406jnj:AsiaPacificAfricaMember2021-01-042021-04-040000200406jnj:EvraAndDoxilMember2021-01-042021-04-040000200406jnj:AsrMember2022-04-03jnj:claimant0000200406jnj:PinnacleAcetabularCupSystemMember2022-04-030000200406jnj:PelvicMeshesMember2022-04-030000200406jnj:RisperdalMember2022-04-030000200406jnj:XareltoMember2022-04-030000200406jnj:TalcMember2022-04-030000200406jnj:InvokanaMember2022-04-030000200406jnj:PhysiomeshMember2022-04-030000200406us-gaap:SettledLitigationMemberjnj:DePuyASRU.S.Member2022-04-03jnj:patient0000200406jnj:PhysiomeshMemberus-gaap:PendingLitigationMember2021-05-31jnj:cases0000200406jnj:PhysiomeshMemberus-gaap:PendingLitigationMember2021-09-300000200406jnj:PhysiomeshMemberus-gaap:PendingLitigationMember2022-04-030000200406us-gaap:JudicialRulingMember2019-10-012019-10-310000200406us-gaap:JudicialRulingMember2020-01-012020-01-310000200406us-gaap:DamagesFromProductDefectsMemberus-gaap:JudicialRulingMemberjnj:BabyPowderMember2018-07-012018-07-310000200406us-gaap:DamagesFromProductDefectsMemberus-gaap:JudicialRulingMemberjnj:BabyPowderMember2020-06-012020-06-300000200406us-gaap:DamagesFromProductDefectsMemberus-gaap:JudicialRulingMemberjnj:BabyPowderMember2021-06-012021-06-300000200406jnj:TalcMemberjnj:BabyPowderMember2021-10-012021-10-310000200406jnj:OpioidMember2022-04-030000200406us-gaap:SettledLitigationMemberjnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember2018-12-312019-12-290000200406us-gaap:PendingLitigationMember2019-10-310000200406us-gaap:PendingLitigationMember2020-10-31jnj:claim0000200406us-gaap:PendingLitigationMember2022-04-030000200406jnj:SurgicalMeshProductsMarketingMemberus-gaap:JudicialRulingMember2020-01-012020-01-310000200406us-gaap:SubsequentEventMemberjnj:SurgicalMeshProductsMarketingMemberus-gaap:JudicialRulingMember2022-04-012022-04-300000200406jnj:ContactLensesMember2015-04-300000200406jnj:SupplyChainMember2022-01-032022-04-030000200406us-gaap:RestructuringChargesMemberjnj:SupplyChainMember2022-01-032022-04-030000200406jnj:SupplyChainMemberus-gaap:CostOfSalesMember2022-01-032022-04-030000200406jnj:OtherIncomeExpenseNetMemberjnj:SupplyChainMember2022-01-032022-04-030000200406jnj:SupplyChainMember2022-04-030000200406jnj:SupplyChainMembersrt:MinimumMember2022-04-030000200406jnj:SupplyChainMembersrt:MaximumMember2022-04-030000200406jnj:MedicalDevicesMemberus-gaap:EmployeeSeveranceMember2022-01-020000200406jnj:MedicalDevicesMemberjnj:AssetWriteoffMember2022-01-020000200406jnj:MedicalDevicesMemberus-gaap:OtherRestructuringMember2022-01-020000200406jnj:MedicalDevicesMember2022-01-020000200406jnj:MedicalDevicesMemberus-gaap:EmployeeSeveranceMember2022-01-032022-04-030000200406jnj:MedicalDevicesMemberjnj:AssetWriteoffMember2022-01-032022-04-030000200406jnj:MedicalDevicesMemberus-gaap:OtherRestructuringMember2022-01-032022-04-030000200406jnj:MedicalDevicesMember2022-01-032022-04-030000200406jnj:MedicalDevicesMemberus-gaap:EmployeeSeveranceMember2022-04-030000200406jnj:MedicalDevicesMemberjnj:AssetWriteoffMember2022-04-030000200406jnj:MedicalDevicesMemberus-gaap:OtherRestructuringMember2022-04-030000200406jnj:MedicalDevicesMember2022-04-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
     
  Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the quarterly period ended April 3, 2022

or
     
  Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the transition period from            to
Commission file number 1-3215
Johnson & Johnson
(Exact name of registrant as specified in its charter)
New Jersey
  22-1024240
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)

One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
(Address of principal executive offices)
Registrant’s telephone number, including area code (732) 524-0400
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company

If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No






SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, Par Value $1.00 JNJ New York Stock Exchange
0.650% Notes Due May 2024 JNJ24C New York Stock Exchange
5.50% Notes Due November 2024 JNJ24BP New York Stock Exchange
1.150% Notes Due November 2028 JNJ28 New York Stock Exchange
1.650% Notes Due May 2035 JNJ35 New York Stock Exchange
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
On April 22, 2022, 2,631,401,804 shares of Common Stock, $1.00 par value, were outstanding.





JOHNSON & JOHNSON AND SUBSIDIARIES
TABLE OF CONTENTS
  Page
  No.
1
   
1
   
1
   
2
3
   
4
5
   
6
   
   
   
   
   
   
   
   





CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q and Johnson & Johnson's other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures.
Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company’s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:
Risks Related to Product Development, Market Success and Competition
Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company’s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;
Challenges to the Company’s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;
The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;
Increasingly aggressive and frequent challenges to the Company’s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;
Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;
Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;
Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and
Allegations that the Company’s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company’s ability to sell the products in question and require the payment of money damages and future royalties.
Risks Related to Product Liability, Litigation and Regulatory Activity
Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;
The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;
The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;



Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;
Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;
Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;
Compliance with local regulations and laws that may restrict the Company’s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union’s Medical Devices Regulation;
Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and
The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.
Risks Related to the Company’s Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Company’s Consumer Health Business
Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;
Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints;
Challenges to the Company’s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;
The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected;
The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected;
The Company’s ability to consummate the planned separation of the Company’s Consumer Health business on a timely basis or at all;
The Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the planned separation; and
The New Consumer Health Company’s ability to succeed as a standalone publicly traded company.
Risks Related to Economic Conditions, Financial Markets and Operating Internationally
The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;
The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;
Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;
The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;
The impact of global public health crises and pandemics, including the novel coronavirus (COVID-19) pandemic;
Changes to global climate, extreme weather and natural disasters that could affect demand for the Company’s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company’s products and operations; and



The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.
Risks Related to Supply Chain and Operations
Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;
Interruptions and breaches of the Company’s information technology systems or those of the Company’s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;
Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company’s products; and
The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.

Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, for a description of certain risks that could, among other things, cause the Company’s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.


Table of Content
Part I — FINANCIAL INFORMATION

Item 1 — FINANCIAL STATEMENTS

JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited; Dollars in Millions Except Share and Per Share Data)
April 3, 2022 January 2, 2022
ASSETS
Current assets:    
Cash and cash equivalents $ 10,463  14,487 
Marketable securities 19,925  17,121 
Accounts receivable, trade, less allowances for doubtful accounts and credit losses $234 (2021, $230)
15,594  15,283 
Inventories (Note 2) 10,990  10,387 
Prepaid expenses and other 3,452  3,701 
Total current assets 60,424  60,979 
Property, plant and equipment at cost 47,702  47,679 
Less: accumulated depreciation (29,001) (28,717)
Property, plant and equipment, net 18,701  18,962 
Intangible assets, net (Note 3) 44,420  46,392 
Goodwill (Note 3) 34,935  35,246 
Deferred taxes on income (Note 5) 9,936  10,223 
Other assets 9,939  10,216 
Total assets $ 178,355  182,018 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:    
Loans and notes payable $ 4,297  3,766 
Accounts payable 9,309  11,055 
Accrued liabilities 13,006  13,612 
Accrued rebates, returns and promotions 12,972  12,095 
Accrued compensation and employee related obligations 2,098  3,586 
Accrued taxes on income (Note 5) 1,708  1,112 
Total current liabilities 43,390  45,226 
Long-term debt (Note 4) 28,851  29,985 
Deferred taxes on income (Note 5) 6,424  7,487 
Employee related obligations (Note 6) 8,739  8,898 
Long-term taxes payable (Note 5) 5,745  5,713 
Other liabilities 10,497  10,686 
Total liabilities $ 103,646  107,995 
Commitments and Contingencies (Note 11)
Shareholders’ equity:    
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)
$ 3,120  3,120 
Accumulated other comprehensive income (loss) (Note 7) (13,757) (13,058)
Retained earnings 124,380  123,060 
Less: common stock held in treasury, at cost (490,459,000 and 490,878,000 shares)
39,034  39,099 
Total shareholders’ equity 74,709  74,023 
Total liabilities and shareholders' equity $ 178,355  182,018 
See Notes to Consolidated Financial Statements
1

Table of Content


JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)
  Fiscal First Quarter Ended
April 3,
2022
Percent
to Sales
April 4,
2021
Percent
to Sales
Sales to customers (Note 9) $ 23,426  100.0  % $ 22,321  100.0  %
Cost of products sold 7,598  32.4  7,063  31.7 
Gross profit 15,828  67.6  15,258  68.3 
Selling, marketing and administrative expenses 5,938  25.4  5,432  24.3 
Research and development expense 3,462  14.8  3,178  14.2 
In-process research and development 610  2.6  —  — 
Interest income (22) (0.1) (15) (0.1)
Interest expense, net of portion capitalized 10  0.0  63  0.3 
Other (income) expense, net (102) (0.4) (882) (3.9)
Restructuring (Note 12) 70  0.3  53  0.2 
Earnings before provision for taxes on income 5,862  25.0  7,429  33.3 
Provision for taxes on income (Note 5) 713  3.0  1,232  5.5 
NET EARNINGS $ 5,149  22.0  % $ 6,197  27.8  %
NET EARNINGS PER SHARE (Note 8)        
Basic $ 1.96    $ 2.35   
Diluted $ 1.93    $ 2.32   
AVG. SHARES OUTSTANDING        
Basic 2,629.2    2,631.6   
Diluted 2,666.5    2,672.7   


See Notes to Consolidated Financial Statements



2

Table of Content
JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited; Dollars in Millions)
Fiscal First Quarter Ended
April 3, 2022 April 4, 2021
Net earnings $ 5,149  6,197 
Other comprehensive income (loss), net of tax
Foreign currency translation (554) 276 
Securities:
  Unrealized holding gain (loss) arising during period (13) — 
  Reclassifications to earnings —  — 
  Net change (13) — 
Employee benefit plans:
  Prior service cost amortization during period (53) (41)
  Gain (loss) amortization during period 217  274 
  Net change 164  233 
Derivatives & hedges:
  Unrealized gain (loss) arising during period (195) (522)
  Reclassifications to earnings (101) (73)
  Net change (296) (595)
Other comprehensive income (loss) (699) (86)
Comprehensive income $ 4,450  6,111 
See Notes to Consolidated Financial Statements
The tax effects in other comprehensive income for the fiscal first quarter were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $145 million and $319 million; Securities: $3 million in 2022; Employee Benefit Plans: $19 million and $66 million; Derivatives & Hedges: $78 million and $157 million.
3

Table of Content
JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited; Dollars in Millions)



Fiscal First Quarter Ended April 3, 2022
Total Retained
Earnings
Accumulated
Other
Comprehensive
Income
Common Stock
Issued Amount
Treasury
Stock
Amount
Balance, January 2, 2022 $ 74,023  123,060  (13,058) 3,120  (39,099)
Net earnings 5,149  5,149  —  —  — 
Cash dividends paid ($1.06 per share)
(2,787) (2,787) —  —  — 
Employee compensation and stock option plans 600  (1,042) —  —  1,642 
Repurchase of common stock (1,577) —  —  —  (1,577)
Other comprehensive income (loss), net of tax (699) —  (699) —  — 
Balance, April 3, 2022 $ 74,709  124,380  (13,757) 3,120  (39,034)






Fiscal First Quarter Ended April 4, 2021
Total Retained
Earnings
Accumulated
Other
Comprehensive
Income
Common Stock
Issued Amount
Treasury
Stock
Amount
Balance, January 3, 2021 $ 63,278  113,890  (15,242) 3,120  (38,490)
Net earnings 6,197  6,197  —  —  — 
Cash dividends paid ($1.01 per share)
(2,659) (2,659) —  —  — 
Employee compensation and stock option plans 542  (920) —  —  1,462 
Repurchase of common stock (1,438) —  —  —  (1,438)
Other comprehensive income (loss), net of tax (86) —  (86) —  — 
Balance, April 4, 2021 $ 65,834  116,508  (15,328) 3,120  (38,466)




See Notes to Consolidated Financial Statements
4

Table of Content
JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; Dollars in Millions)
  Fiscal Three Months Ended
April 3,
2022
April 4,
2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net earnings $ 5,149  6,197 
Adjustments to reconcile net earnings to cash flows from operating activities:    
Depreciation and amortization of property and intangibles 1,769  1,894 
Stock based compensation 278  307 
Asset write-downs 610  14 
Net gain on sale of assets/businesses (168) (580)
Deferred tax provision (926) (730)
Credit losses and accounts receivable allowances (13)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:    
Increase in accounts receivable (427) (1,604)
Increase in inventories (600) (695)
Decrease in accounts payable and accrued liabilities (2,817) (2,336)
Decrease in other current and non-current assets 995  2,522 
Increase/(Decrease) in other current and non-current liabilities 110  (902)
NET CASH FLOWS FROM OPERATING ACTIVITIES 3,979  4,074 
CASH FLOWS FROM INVESTING ACTIVITIES    
Additions to property, plant and equipment (607) (677)
Proceeds from the disposal of assets/businesses, net (Note 10) 248  603 
Acquisitions, net of cash acquired (Note 10) (252) — 
Purchases of investments (9,018) (5,994)
Sales of investments 6,303  5,233 
Credit support agreements activity, net (249) 751 
Other (primarily licenses and milestones) (59) (101)
NET CASH USED BY INVESTING ACTIVITIES (3,634) (185)
CASH FLOWS FROM FINANCING ACTIVITIES    
Dividends to shareholders (2,787) (2,659)
Repurchase of common stock (1,577) (1,438)
Proceeds from short-term debt 3,019  23 
Repayment of short-term debt (856) (475)
Proceeds from long-term debt, net of issuance costs — 
Repayment of long-term debt (2,132) (1,001)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 321  236 
Credit support agreements activity, net (235) 212 
Other (138) (24)
NET CASH USED BY FINANCING ACTIVITIES (4,385) (5,125)
Effect of exchange rate changes on cash and cash equivalents 16  (78)
Decrease in cash and cash equivalents (4,024) (1,314)
Cash and Cash equivalents, beginning of period 14,487  13,985 
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 10,463  12,671 
Acquisitions
Fair value of assets acquired $ 255  — 
Fair value of liabilities assumed and noncontrolling interests (3) — 
Net cash paid for acquisitions $ 252  — 
See Notes to Consolidated Financial Statements
5

Table of Content
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.

Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.

Use of Estimates
The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April 3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company’s on-going vaccine development and distribution efforts. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended April 3, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.

New Accounting Standards
The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022. There were no new material accounting standards issued in the fiscal first quarter of 2022 that impacted the Company.

Recently Adopted Accounting Standards
There were no new material accounting standards adopted in the fiscal first quarter of 2022.

Reclassification
Certain prior period amounts have been reclassified to conform to current year presentation.




NOTE 2 — INVENTORIES
(Dollars in Millions) April 3, 2022 January 2, 2022
Raw materials and supplies $ 1,679  1,592 
Goods in process 2,629  2,287 
Finished goods 6,682  6,508 
Total inventories $ 10,990  10,387 


6

Table of Content
NOTE 3 — INTANGIBLE ASSETS AND GOODWILL

Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.
(Dollars in Millions) April 3, 2022 January 2, 2022
Intangible assets with definite lives:    
Patents and trademarks — gross $ 37,960  38,572 
Less accumulated amortization (20,492) (20,088)
Patents and trademarks — net 17,468  18,484 
Customer relationships and other intangibles — gross 22,910  23,011 
Less accumulated amortization (12,147) (11,925)
Customer relationships and other intangibles — net(1)
10,763  11,086 
Intangible assets with indefinite lives:    
Trademarks 6,947  6,985 
Purchased in-process research and development(2)
9,242  9,837 
Total intangible assets with indefinite lives 16,189  16,822 
Total intangible assets — net $ 44,420  46,392 
(1)The majority is comprised of customer relationships
(2)In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020.

Goodwill as of April 3, 2022 was allocated by segment of business as follows:
(Dollars in Millions) Consumer Health Pharmaceutical MedTech Total
Goodwill at January 2, 2022 $ 9,810  10,580  14,856  35,246 
Goodwill, related to acquisitions —  —  73  73 
Currency translation/Other (195) (170) (19) (384)
Goodwill at April 3, 2022 $ 9,615  10,410  14,910  34,935 

The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion and $1.2 billion for the fiscal first quarters ended April 3, 2022 and April 4, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net.

The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
2022 2023 2024 2025 2026
$4,600 4,600 4,400 3,600 3,000

See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

7

Table of Content

NOTE 4 — FAIR VALUE MEASUREMENTS

The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.

Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.

The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April 3, 2022, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $1.1 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April 3, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $42.5 billion, $37.4 billion and $10.0 billion, respectively. As of January 2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion, $37.4 billion and $10.0 billion respectively.

All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.

The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.

Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.

The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.

As of April 3, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $632 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.

8

Table of Content


The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2022 and 2021, net of tax:
April 3, 2022 April 4, 2021
(Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
    Hedged items $ —  —  —  (531) —  —  —  —  —  — 
    Derivatives designated as hedging instruments —  —  —  531  —  —  —  —  —  — 
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing —  —  —  45  —  —  —  —  40  — 
   Amount of gain or (loss) recognized in AOCI —  —  —  45  —  —  —  —  40  — 
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
   Amount of gain or (loss) reclassified from AOCI into income (17) (52) 23  —  (18) 17  34  (113) — 
   Amount of gain or (loss) recognized in AOCI 22  (94) 33  —  (73) (3) (193) (76) —  17 
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) reclassified from AOCI into income —  —  —  120  —  —  —  92  — 
   Amount of gain or (loss) recognized in AOCI $ —  —  —  (128) —  —  —  —  (307) — 









9

Table of Content




As of April 3, 2022, and January 2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges
Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability
Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability
(Dollars in Millions) April 3, 2022 January 2, 2022 April 3, 2022 January 2, 2022
Long-term Debt 9,313  9,793  (694) (142)


The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2022 and 2021:
Gain/(Loss)
Recognized In
Income on Derivative
(Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal First Quarter Ended
Derivatives Not Designated as Hedging Instruments April 3, 2022 April 4, 2021
Foreign Exchange Contracts Other (income) expense $ 29  (16)


The following table is the effect of net investment hedges for the fiscal first quarters ended in 2022 and 2021:
Gain/(Loss)
Recognized In
Accumulated
OCI
Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions) April 3, 2022 April 4, 2021 April 3, 2022 April 4, 2021
Debt $ 68  209  Interest (income) expense —  — 
Cross Currency interest rate swaps $ 560  361  Interest (income) expense —  — 



The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair
10

Table of Content
values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
The following table is a summary of the activity related to equity investments:
(Dollars in Millions) January 2, 2022 April 3, 2022
Carrying Value
Changes in Fair Value Reflected in Net Income (1)
Sales/ Purchases/Other (2)
Carrying Value Non Current Other Assets
Equity Investments with readily determinable value $ 1,884  (402) (30) 1,452  1,452 
Equity Investments without readily determinable value $ 500  (5) 10  505  505 
(1) Recorded in Other Income/Expense
(2) Other includes impact of currency

For equity investments without readily determinable market values, there was a decrease of $5 million in the fair value reflected in net income as a result of impairments.

Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.

The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.

The following three levels of inputs are used to measure fair value:

Level 1 — Quoted prices in active markets for identical assets and liabilities.
Level 2 — Significant other observable inputs.
Level 3 — Significant unobservable inputs.

11

Table of Content
The Company’s significant financial assets and liabilities measured at fair value as of April 3, 2022 and January 2, 2022 were as follows:
  April 3, 2022   January 2, 2022
(Dollars in Millions) Level 1 Level 2 Level 3 Total
Total(1)
Derivatives designated as hedging instruments:          
Assets:          
Forward foreign exchange contracts $ —  742  —  742  540 
Interest rate contracts (2)
—  975  —  975  796 
Total —  1,717  —  1,717  1,336 
Liabilities:          
Forward foreign exchange contracts —  1,058  —  1,058  881 
Interest rate contracts (2)
—  1,652  —  1,652  979 
Total —  2,710  —  2,710  1,860 
Derivatives not designated as hedging instruments:          
Assets:          
Forward foreign exchange contracts —  36  —  36  24 
Liabilities:          
Forward foreign exchange contracts —  68  —  68  28 
Other Investments:
Equity investments (3)
1,452  —  —  1,452  1,884 
Debt securities (4)
—  19,583  —  19,583  19,727 
Other Liabilities
Contingent consideration (5)
$ —  —  486  486  533 

Gross to Net Derivative Reconciliation April 3, 2022 January 2, 2022
(Dollars in Millions)
Total Gross Assets $ 1,753  1,360 
Credit Support Agreement (CSA) (1,655) (1,285)
Total Net Asset 98  75 
Total Gross Liabilities 2,778  1,888 
Credit Support Agreement (CSA) (2,709) (1,855)
Total Net Liabilities $ 69  33 

12

Table of Content


Summarized information about changes in liabilities for contingent consideration is as follows:
April 3, 2022 April 4, 2021
(Dollars in Millions)
Beginning Balance $ 533  $ 633 
Changes in estimated fair value (6)
(47) 15 
Additions —  — 
Payments —  (48)
Ending Balance $ 486  $ 600 

(1)2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.
(2) Includes cross currency interest rate swaps and interest rate swaps.
(3)    Classified as non-current other assets.
(4)    Classified within cash equivalents and current marketable securities.
(5)    Includes $469 million and $520 million, classified as non-current other liabilities as of April 3, 2022 and January 2, 2022, respectively. Includes $17 million and $13 million classified as current liabilities as of April 3, 2022 and January 2, 2022, respectively.
(6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.

The Company's cash, cash equivalents and current marketable securities as of April 3, 2022 comprised:
(Dollars in Millions) Carrying Amount Gain/( Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities
Cash $ 3,128  —  3,128  3,128  — 
Non-U.S. sovereign securities(1)
329  —  329  —  329 
U.S. reverse repurchase agreements 1,449  —  1,449  1,449  — 
Corporate debt securities(1)
3,557  (6) 3,551  540  3,017 
Money market funds 1,579  —  1,579  1,579  — 
Time deposits(1)
763  —  763  763  — 
   Subtotal 10,805  (6) 10,799  7,459  3,346 
Unrealized Loss
U.S. Gov't securities 19,354  (19) 19,335  2,968  16,367 
Other sovereign securities —  — 
Corporate debt securities 246  (1) 245  36  209 
   Subtotal available for sale debt(2)
$ 19,603  (20) 19,583  3,004  16,579 
Total cash, cash equivalents and current marketable securities $ 30,408  (26) 30,382  10,463  19,925 
(1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.
(2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.

13

Table of Content

As of the fiscal year ended January 2, 2022 the carrying amount was approximately the same as the estimated fair value.

Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.

The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.

The contractual maturities of the available for sale securities as of April 3, 2022 are as follows:
(Dollars in Millions) Cost Basis Fair Value
Due within one year $ 19,585  19,564 
Due after one year through five years 19  19 
Due after five years through ten years —  — 
Total debt securities $ 19,604  19,583 
14

Table of Content

Financial Instruments not measured at Fair Value:
The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April 3, 2022:
(Dollars in Millions) Carrying Amount Estimated Fair Value
Financial Liabilities    
Current Debt $ 4,297  4,298 
Non-Current Debt    
6.73% Debentures due 2023
250  266 
3.375% Notes due 2023
802  820 
0.650% Notes due 2024 (750MM Euro 1.1311)
824  829 
5.50% Notes due 2024 (500 MM GBP 1.3485)
654  713 
2.625% Notes due 2025
749  762 
0.55% Notes due 2025
950  886 
2.45% Notes due 2026
1,995  1,981 
2.95% Notes due 2027
930  934 
0.95% Notes due 2027
1,436  1,307 
2.90% Notes due 2028
1,496  1,489 
1.150% Notes due 2028 (750MM Euro 1.1311)
826  829 
6.95% Notes due 2029
298  379 
1.30% Notes due 2030
1,672  1,486 
4.95% Debentures due 2033
498  590 
4.375% Notes due 2033
855  959 
1.650% Notes due 2035 (1.5B Euro 1.1311)
1,654  1,687 
3.55% Notes due 2036
917  947 
5.95% Notes due 2037
993  1,288 
3.625% Notes due 2037
1,416  1,463 
3.40% Notes due 2038
992  999 
5.85% Debentures due 2038
697  901 
4.50% Debentures due 2040
540  617 
2.10% Notes due 2040
914  777 
4.85% Notes due 2041
297  342 
4.50% Notes due 2043
496  565 
3.70% Notes due 2046
1,975  2,097 
3.75% Notes due 2047
906  969 
3.50% Notes due 2048
743  766 
2.25% Notes due 2050
914  759 
2.45% Notes due 2060
1,155  942 
Other
Total Non-Current Debt $ 28,851  29,356 

The weighted average effective interest rate on non-current debt is 3.04%.

The excess of the estimated fair value over the carrying value of debt was $3.2 billion at January 2, 2022.

The current debt balance as of April 3, 2022 includes $3.8 billion of commercial paper which has a weighted average interest rate of 0.37% and a weighted average maturity of approximately three months.
15

Table of Content

Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

NOTE 5 — INCOME TAXES

The worldwide effective income tax rates for the fiscal first quarters of 2022 and 2021 were 12.2% and 16.6%, respectively. This decrease in the consolidated tax rate is primarily due to lower income in higher tax jurisdictions, primarily in the U.S., compared to the same period in the prior year. This lower income in the first fiscal quarter of 2022 was caused by a mark to market adjustment to the Company’s investment portfolio and the impairment of the bermekimab AD IPR&D (for further information see Note 3 of the Consolidated Financial Statements), both at the U.S. statutory rate. The impact of the income mix was partially offset by incremental tax costs directly related to the planned separation of the Company’s Consumer Health business.

The Company also had tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal first quarters. Additionally, the Company’s effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal year 2022.

As of April 3, 2022, the Company had approximately $3.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.


NOTE 6 — PENSIONS AND OTHER BENEFIT PLANS

Components of Net Periodic Benefit Cost
Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components:
Fiscal First Quarter Ended
  Retirement Plans Other Benefit Plans
(Dollars in Millions) April 3, 2022 April 4, 2021 April 3, 2022 April 4, 2021
Service cost $ 321  353  80  77 
Interest cost 230  193  26  20 
Expected return on plan assets (699) (680) (2) (2)
Amortization of prior service cost/(credit) (46) (45) (1) (8)
Recognized actuarial losses 162  314  30  38 
Curtailments and settlements —  — 
Net periodic benefit cost/(credit) $ (31) 136  133  125 

The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.

Company Contributions
For the fiscal three months ended April 3, 2022, the Company contributed $29 million and $5 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.



16

Table of Content
NOTE 7 — ACCUMULATED OTHER COMPREHENSIVE INCOME

Components of other comprehensive income (loss) consist of the following:
  Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated
Currency On Benefit On Derivatives Other Comprehensive
(Dollars in Millions) Translation Securities Plans & Hedges Income (Loss)
January 2, 2022 $ (10,017) (3) (2,702) (336) (13,058)
Net change (554) (13) 164  (296) (699)
April 3, 2022 $ (10,571) (16) (2,538) (632) (13,757)

Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.

Details on reclassifications out of Accumulated Other Comprehensive Income:
Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.
Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.
Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.
17

Table of Content

NOTE 8 — EARNINGS PER SHARE

The following is a reconciliation of basic net earnings per share to diluted net earnings per share:
  Fiscal First Quarter Ended
(Shares in Millions) April 3, 2022 April 4, 2021
Basic net earnings per share $ 1.96  2.35 
Average shares outstanding — basic 2,629.2  2,631.6 
Potential shares exercisable under stock option plans 140.1  128.4 
Less: shares which could be repurchased under treasury stock method (102.8) (87.3)
Average shares outstanding — diluted 2,666.5  2,672.7 
Diluted net earnings per share $ 1.93  2.32 

The diluted net earnings per share calculation for the fiscal first quarter ended April 3, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company’s stock.

The diluted net earnings per share calculation for the fiscal first quarter ended April 4, 2021 excluded 9 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock.


18

Table of Content
NOTE 9 — SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS

SALES BY SEGMENT OF BUSINESS
  Fiscal First Quarter Ended
(Dollars in Millions) April 3,
2022
April 4,
2021
Percent
Change
CONSUMER HEALTH      
OTC(1)
     U.S. $ 670  599  11.8  %
     International 791  673  17.5 
     Worldwide 1,461  1,273  14.8 
Skin Health/Beauty
     U.S. 544  634  (14.2)
     International 468  529  (11.6)
     Worldwide 1,012  1,163  (13.0)
Oral Care
     U.S. 143  163  (12.6)
     International 223  254  (12.0)
     Worldwide 366  417  (12.2)
Baby Care
     U.S. 85  96  (11.5)
     International 270  293  (7.7)
     Worldwide 355  389  (8.6)
Women's Health
     U.S. 7.2 
     International 224  219  2.5 
     Worldwide 228  222  2.6 
Wound Care/Other
     U.S. 112  115  (3.3)
     International 52  61  (15.3)
     Worldwide 164  177  (7.4)
TOTAL CONSUMER HEALTH
     U.S. 1,557  1,611  (3.4)
     International 2,029  2,030  0.0
     Worldwide 3,586  3,641  (1.5)
19

Table of Content
PHARMACEUTICAL
Immunology
     U.S. 2,501  2,413  3.7 
     International 1,617  1,501  7.7 
     Worldwide 4,119  3,914  5.2 
     REMICADE
     U.S. 358  489  (26.8)
     U.S. Exports 80  57  40.5 
     International 225  232  (2.6)
     Worldwide 663  777  (14.7)
     SIMPONI / SIMPONI ARIA
     U.S. 287  255  12.5 
     International 283  307  (7.6)
     Worldwide 571  562  1.5 
     STELARA
     U.S. 1,379  1,331  3.6 
     International 909  817  11.2 
     Worldwide 2,288  2,148  6.5 
     TREMFYA
     U.S. 391  274  42.7 
     International 199  143  38.8 
     Worldwide 590  418  41.3 
     OTHER IMMUNOLOGY
     U.S. (3.2)
     International *
     Worldwide (22.0)
Infectious Diseases
     U.S. 461  512  (10.0)
     International 836  485  72.3 
     Worldwide 1,297  998  30.0 
     COVID-19 VACCINE
     U.S. 75  100  (24.9)
     International 382  0 *
     Worldwide 457  100  *
     EDURANT / rilpivirine
     U.S. 10  (12.6)
     International 239  233  2.5 
     Worldwide 248  243  1.8 
      PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     U.S. 369  380  (3.1)
     International 132  166  (20.3)
     Worldwide 501  546  (8.3)
20

Table of Content
     OTHER INFECTIOUS DISEASES(1)
     U.S. 21  (62.5)
     International 83  87  (3.8)
     Worldwide 91  108  (15.3)
Neuroscience
     U.S. 843  771  9.3 
     International 898  943  (4.8)
     Worldwide 1,741  1,715  1.5 
     CONCERTA / methylphenidate
     U.S. 35  47  (26.5)
     International 122  123  (1.3)
     Worldwide 157  171  (8.3)
     INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
     U.S. 661  589  12.2 
     International 387  376  3.0 
     Worldwide 1,048  965  8.6 
     RISPERDAL CONSTA
     U.S. 63  67  (6.4)
     International 66  89  (26.1)
     Worldwide 129  157  (17.6)
     OTHER NEUROSCIENCE(1)
     U.S. 84  67  25.5 
     International 323  355  (8.9)
     Worldwide 408  422  (3.5)
Oncology
     U.S. 1,582  1,377  14.9 
     International 2,369  2,193  8.0 
     Worldwide 3,950  3,570  10.6 
     DARZALEX
     U.S. 953  691  37.9 
     International 903  674  34.0 
     Worldwide 1,856  1,365  36.0 
     ERLEADA
     U.S. 206  171  20.3 
     International 194  90   *
     Worldwide 400  261  53.0 
     IMBRUVICA
     U.S. 370  444  (16.7)
     International 668  680  (1.8)
     Worldwide 1,038  1,125  (7.7)
     ZYTIGA / abiraterone acetate
     U.S. 19  50  (62.1)
     International 520  588  (11.6)
     Worldwide 539  638  (15.6)
21

Table of Content
     OTHER ONCOLOGY
     U.S. 34  21  63.1 
     International 84  161  (47.7)
     Worldwide 118  182  (35.1)
Pulmonary Hypertension
     U.S. 572  573  (0.2)
     International 279  288  (2.9)
     Worldwide 852  861  (1.1)
     OPSUMIT
     U.S. 273  272  0.5 
     International 170  179  (4.8)
     Worldwide 443  450  (1.6)
     UPTRAVI
     U.S. 269  259  3.9 
     International 56  46  20.9 
     Worldwide 325  305  6.5 
     OTHER PULMONARY HYPERTENSION
     U.S. 30  42  (29.0)
     International 53  63  (15.2)
     Worldwide 83  105  (20.8)
Cardiovascular / Metabolism / Other
     U.S. 672  799  (15.8)
     International 238  245  (3.0)
     Worldwide 910  1,044  (12.8)
     XARELTO
     U.S. 508  589  (13.8)
     International —  —  — 
     Worldwide 508  589  (13.8)
     INVOKANA / INVOKAMET
     U.S. 60  87  (30.7)
     International 68  63  7.5 
     Worldwide